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Abstract 
Synthetic lethality is a promising approach in precision medicine and cancer 
as it largely expands the number of possible drug targets and creates an 
opportunity for selectivity. The increasing evidence of metabolic 
reprogramming of cancer cells makes it ideal to exploit the concept of 
synthetic lethality. A number of in-silico tools have been developed to target 
cancer metabolism using a synthetic lethality approach. In particular, 
constraint-based modeling (CBM) for genome- scale metabolic networks has 
received much attention. Here, we present a novel CBM approach to synthetic 
lethality that is based on the concept of genetic Minimal Cut Sets (gMCSs). 
With respect to existing methods, our approach avoids the step of network 
contextualization and integrates –omics data in a more natural and objective 
manner. In addition, it enables not only the detection metabolic targets but 
also response biomarkers for them. To illustrate our approach, we first show 
the results of an experimental proof-of-concept in multiple myeloma (MM), 
where we validated the therapeutic potential of RRM1 inhibition in different MM 
cell lines. We also predicted a metabolic signature based on gene expression 
data that explained the response to RRM1 inhibition in different cancer cell 
lines. Second, we show preliminary results of a study where response 
biomarkers for the effectiveness of Methotrexate in different cancer types is 
predicted following our methodology. This new algorithm, freely available in 
the COBRA Toolbox, undoubtedly opens new avenues to develop precision 
medicine strategies in complex and unaddressed clinical questions involving 
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